Drug Discovery World

MAY 7, 2024

Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. What effect has antibody engineering had on drug discovery and development? The post Where is the opportunity in the therapeutic antibody market? Watch the webinar on-demand now!

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

pharmaphorum

APRIL 22, 2022

Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three gene therapy candidates for Duchenne muscular dystrophy in preclinical development. The post Astellas takes $170m charge as it drops DMD gene therapies appeared first on.

Gene Therapy 105

Gene Therapy Gene DNA Licensing 105

Drug Discovery World

FEBRUARY 21, 2024

We are delighted to be further backing MIP as they are making significant technical progress.” The post £7M financing to drive commercialisation in cell and gene therapy appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Reagent Production 52

Bio Pharma Dive

DECEMBER 1, 2020

Working with University of Pennsylvania researcher Jim Wilson, Regeneron aims to develop a nasal spray version of the coronavirus treatment recently cleared by the Food and Drug Administration.

Gene Therapy 270

Gene Therapy Antibody Gene Drugs 270

Drug Discovery World

APRIL 8, 2024

Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. Dr Levy will outline the significance of belimumab, a monoclonal antibody that inhibits B-cell activating factor. What effect has antibody engineering had on drug discovery and development?

Antibody 59

Antibody Marketing Gene Therapy Engineer 59

Drug Discovery World

AUGUST 7, 2023

By enhancing the precision of gene delivery to heart muscle cells and evading the immune response, exoAAV technology has the potential to redefine the use of gene therapy in the cardiovascular disease field.

Gene Therapy 52

Gene Therapy Gene Research In-Vivo 52

XTalks

JUNE 28, 2023

Gene therapies for Duchenne muscular dystrophy (DMD) have been an area of intense research and Sarepta’s Elevidys is now the first one to be approved by the US Food and Drug Administration (FDA). million price tag of Elevidys, a one-time gene therapy. Options for managing the symptoms of DMD have been limited.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

Drug Discovery World

APRIL 22, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Development Gene Therapy Marketing 52

Drug Discovery World

APRIL 29, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

pharmaphorum

OCTOBER 6, 2021

Voyager Therapeutics has just landed a new gene therapy alliance with Pfizer that could go some way towards easing the pain of losing three other partners in the space of a couple of years. The post Pfizer agrees $630m deal to harness Voyager’s gene therapy tech appeared first on.

Gene Therapy 105

Gene Therapy Gene Antibody Manufacturing 105

pharmaphorum

SEPTEMBER 13, 2021

AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for wet age-related macular degeneration (AMD) and other eye diseases. The post AbbVie spies potential in Regenxbio eye disease gene therapy appeared first on.

Gene Therapy 97

Gene Therapy Gene Sales Trials 97

Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

FDA Law Blog

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Gene Therapy 119

Gene Therapy Gene FDA Approval Production 119

pharmaphorum

APRIL 16, 2021

The 2 nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. Performances of biosafety analytical assays commonly used in gene therapy development.

Gene Therapy 52

Gene Therapy Gene Immune Response Antibody 52

BioTech 365

FEBRUARY 10, 2021

Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies Fully integrated gene therapy offering, including platform technology, pipeline development, and manufacturing capabilities Targeting muscular and … Continue reading (..)

Gene Therapy 52

Gene Therapy Antibody Gene Development 52

FDA Law Blog

MARCH 13, 2023

This meeting will host a panel of rare disease patients, caregivers, and advocates to have a focused discussion on the emerging field of gene therapy (regulated at the FDA by OTP). At least some (if not all) of the panelists will have had experience participating in gene therapy trials.

Gene Therapy 98

Gene Therapy Gene Trials Clinical Trials 98

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

pharmaphorum

MARCH 8, 2022

Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with Novartis taking an option on three neurological disease programmes. billion including fees and milestones.

Gene Therapy 52

Gene Therapy Gene Antibody Development 52

Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Companies Offering Bioassay Services for Cell and Gene Therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

MAY 7, 2024

DDW Editor Reece Armstrong speaks to David Chau , Global Bioprocess Application Specialist, Separation and Purification Sciences Division, 3M, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes. RA: What are some of the current limitations for producing mAbs? He earned his Ph.D

Antibody 59

Antibody Production Manufacturing Engineer 59

BioTech 365

DECEMBER 1, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies.Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies … Continue reading →

Gene Therapy 40

Gene Therapy Gene Antibody Research 40

Drug Discovery World

DECEMBER 21, 2023

In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Read the article – Expert view: What’s next for cell and gene therapy?

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Pharmaceutical Technology

APRIL 14, 2023

Twist Bioscience CEO and co-founder Emily Leproust said: “With the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases.

Development 246

Development Gene Therapy Gene Antibody 246

Pharmaceutical Technology

JANUARY 17, 2023

The STAb therapy is based on a special type of bispecific antibody secretion. This antibody can detect targets on the tumour cell and the T cell. An artificial bridge created by these antibodies gets therapeutic T cells and tumour cells into contact. By Cytiva Thematic.

Development 276

Development Gene Therapy Antibody Gene 276

BioPharma Reporter

DECEMBER 2, 2021

Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.

Gene Therapy 97

Gene Therapy Antibody Gene Manufacturing 97

pharmaphorum

JUNE 17, 2021

Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The post Biogen abandons tau antibody for Alzheimer’s after phase 2 miss appeared first on.

Antibody 98

Antibody Protein Licensing Licensing 98

pharmaphorum

JANUARY 12, 2024

Discover the top six key takeaways from JP Morgan's 2024 conference, focusing on dealmaking trends in big tech, life science, AI, and advancements in cell and gene therapies, as well as the future of Antibody-drug conjugates (ADCs). Stay informed with the latest industry insights.

Gene Therapy 59

Gene Therapy Life Science Antibody Gene 59

Drug Discovery World

FEBRUARY 19, 2024

This move indicates that, despite the financial downturn, there are still acquisitions and funding releases, particularly in the gene therapy space and for those developing promising small molecule or biologic products that are potentially transformative for patients and where a relatively short timeline to market is likely (e.g.

Development 59

Development Gene Therapy Drugs Antibody 59

pharmaphorum

NOVEMBER 30, 2020

Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

Pharmaceutical Technology

NOVEMBER 22, 2022

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

Manufacturing 162

Manufacturing Gene Therapy Gene Contract Manufacturing 162

Delveinsight

DECEMBER 22, 2020

FDA Puts uniQure’s Hemophilia B Gene Therapy on Leash. In a recent, uniQure faced backlash after its hemophilia B gene therapy got hit with clinical hold by the USFDA. . The Hemophilia B market has several therapies, however, no therapy has been able to kill the disease from its root.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

STAT News

DECEMBER 22, 2022

Merck has agreed to pay $175 million in cash to Kelun-Biotech, a division of the Chinese pharmaceutical firm Sichuan Kelun Pharmaceutical, for the rights to seven preclinical antibody-drug conjugates, a type of cancer drug that has seen some big successes recently. billion.

Gene Therapy 98

Gene Therapy Gene Drugs Licensing 98

Delveinsight

FEBRUARY 18, 2021

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer. Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cortexyme tripped up by FDA hold over liver toxicity.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Pharmaceutical Technology

APRIL 27, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Roche ’s Columvi (glofitamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients after receiving two or more lines of systemic therapy.

Gene Therapy 130

Gene Therapy Antibody Gene Medicine 130